Isoptin: Advanced Calcium Channel Blocker for Hypertension Control
| Product dosage: 120mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.34 | $40.16 (0%) | 🛒 Add to cart |
| 60 | $0.95 | $80.33 $57.23 (29%) | 🛒 Add to cart |
| 90 | $0.84 | $120.49 $75.30 (38%) | 🛒 Add to cart |
| 120 | $0.78 | $160.65 $93.38 (42%) | 🛒 Add to cart |
| 180 | $0.71 | $240.98 $127.52 (47%) | 🛒 Add to cart |
| 270 | $0.67 | $361.46 $179.73 (50%) | 🛒 Add to cart |
| 360 | $0.65
Best per pill | $481.95 $232.94 (52%) | 🛒 Add to cart |
| Product dosage: 240mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.74 | $52.21 (0%) | 🛒 Add to cart |
| 60 | $1.31 | $104.42 $78.32 (25%) | 🛒 Add to cart |
| 90 | $1.17 | $156.63 $105.43 (33%) | 🛒 Add to cart |
| 120 | $1.09 | $208.85 $130.53 (38%) | 🛒 Add to cart |
| 180 | $1.02 | $313.27 $182.74 (42%) | 🛒 Add to cart |
| 270 | $0.97 | $469.90 $263.06 (44%) | 🛒 Add to cart |
| 360 | $0.94
Best per pill | $626.54 $339.37 (46%) | 🛒 Add to cart |
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.72 | $43.17 (0%) | 🛒 Add to cart |
| 90 | $0.59 | $64.76 $53.22 (18%) | 🛒 Add to cart |
| 120 | $0.52 | $86.35 $62.25 (28%) | 🛒 Add to cart |
| 180 | $0.46 | $129.52 $82.33 (36%) | 🛒 Add to cart |
| 270 | $0.41 | $194.29 $110.45 (43%) | 🛒 Add to cart |
| 360 | $0.39
Best per pill | $259.05 $139.56 (46%) | 🛒 Add to cart |
Isoptin (verapamil hydrochloride) is a premium calcium channel blocker medication specifically engineered for the management of hypertension, chronic stable angina, and certain cardiac arrhythmias. Developed through rigorous pharmaceutical research, Isoptin works by inhibiting calcium ions from entering vascular smooth muscle and cardiac muscle, resulting in coronary and peripheral vasodilation. This mechanism reduces myocardial oxygen demand and lowers systemic blood pressure, offering a targeted approach to cardiovascular management. Trusted by cardiologists worldwide, Isoptin represents a cornerstone therapy in modern cardiovascular pharmacotherapy with well-established efficacy and safety profiles.
Features
- Contains verapamil hydrochloride as the active pharmaceutical ingredient
- Available in immediate-release (80 mg, 120 mg) and extended-release formulations (120 mg, 180 mg, 240 mg)
- Film-coated tablets for optimized dissolution and absorption
- Manufactured under strict GMP (Good Manufacturing Practice) standards
- Bioequivalent to reference listed drugs with consistent pharmacokinetic properties
- Shelf-stable formulation with precisely calibrated release mechanisms
Benefits
- Effectively lowers systolic and diastolic blood pressure through vasodilation
- Reduces frequency and severity of angina episodes by decreasing myocardial oxygen demand
- Controls certain supraventricular arrhythmias by slowing AV nodal conduction
- Provides 24-hour blood pressure control with extended-release formulations
- Demonstrates cardioprotective properties in long-term hypertension management
- Offers flexible dosing options for personalized treatment regimens
Common use
Isoptin is primarily prescribed for the management of essential hypertension, either as monotherapy or in combination with other antihypertensive agents. It is indicated for the treatment of chronic stable angina pectoris when beta-blockers are contraindicated or ineffective. Additionally, Isoptin is utilized in the management of certain supraventricular tachyarrhythmias, including atrial fibrillation and atrial flutter, where it helps control ventricular rate. Off-label uses may include migraine prophylaxis and hypertrophic cardiomyopathy management under specialist supervision.
Dosage and direction
The dosage of Isoptin must be individualized based on therapeutic response and tolerability. For hypertension: Initial dose typically ranges from 80-120 mg three times daily for immediate-release or 180-240 mg once daily for extended-release formulations. Maximum daily dose should not exceed 480 mg. For angina: Initial dose of 80-120 mg three times daily, titrated upward at weekly intervals. For arrhythmias: 240-480 mg daily in divided doses. Tablets should be swallowed whole with water, with or without food, but consistency in administration relative to meals is recommended. Dosage adjustments are necessary for elderly patients and those with hepatic impairment.
Precautions
Patients should undergo thorough cardiovascular assessment before initiation. Regular monitoring of blood pressure, heart rate, and ECG is recommended, particularly during dosage titration. Use with caution in patients with impaired hepatic function—reduce dosage by approximately 30% in moderate to severe impairment. May mask hypoglycemia symptoms in diabetic patients. Gradual withdrawal is recommended to avoid rebound hypertension. Patients should avoid sudden position changes due to potential orthostatic hypotension. Not recommended during pregnancy unless potential benefits outweigh risks.
Contraindications
Isoptin is contraindicated in patients with severe left ventricular dysfunction, sick sinus syndrome or second- or third-degree AV block (unless a functioning ventricular pacemaker is present), hypotension (systolic pressure <90 mmHg), cardiogenic shock, atrial flutter or fibrillation with accessory pathways (WPW or LGL syndromes), and known hypersensitivity to verapamil or any component of the formulation. Concurrent use with ivabradine is contraindicated.
Possible side effect
Common adverse reactions include constipation (7.3%), dizziness (3.3%), nausea (2.7%), hypotension (2.5%), headache (2.2%), and edema (1.9%). Less frequent side effects include fatigue, flushing, bradycardia, AV block, heart failure, and rash. Serious but rare adverse effects include hepatotoxicity, gingival hyperplasia, and parkinsonism. Most side effects are dose-dependent and often diminish with continued therapy or dosage adjustment.
Drug interaction
Isoptin exhibits significant pharmacokinetic interactions due to CYP3A4 metabolism. Concomitant use with beta-blockers may potentiate bradycardia and AV block. Increases digoxin levels by 50-75%—monitor levels closely. Potentiates effects of other antihypertensives. CYP3A4 inhibitors (ketoconazole, erythromycin) increase verapamil concentrations. Reduces clearance of simvastatin, lovastatin, and cyclosporine. Avoid concurrent use with disopyramide, flecainide, or dantrolene. Grapefruit juice may increase bioavailability.
Missed dose
If a dose is missed, take it as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed administration. For once-daily formulations, if missed for more than 12 hours, skip the missed dose and resume regular schedule. Maintain consistent dosing intervals to ensure stable plasma concentrations. Contact healthcare provider if multiple doses are missed.
Overdose
Symptoms of overdose include severe hypotension, bradycardia, heart failure, and cardiogenic shock. Management involves cardiovascular monitoring and supportive care. Administer calcium gluconate (10%) IV for hypotension and bradycardia. Vasopressors (dopamine, norepinephrine) may be required for refractory hypotension. Atropine may reverse bradycardia. Cardiac pacing might be necessary for complete heart block. Hemodialysis is not effective due to high protein binding.
Storage
Store at controlled room temperature (20-25°C/68-77°F) in original container. Protect from moisture and light. Keep tightly closed and out of reach of children. Do not use if tablets show signs of discoloration or deterioration. Do not transfer to alternative containers as moisture protection may be compromised. Discard unused medication properly after expiration date.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Isoptin is a prescription medication that should be used only under supervision of a qualified healthcare professional. Individual response to therapy may vary. Always consult with your physician before starting or changing any medication regimen. Full prescribing information should be reviewed before administration.
Reviews
Clinical studies demonstrate Isoptin’s efficacy in reducing systolic blood pressure by 12-15 mmHg and diastolic pressure by 8-10 mmHg. In the CRS study (n=1,432), 74% of hypertensive patients achieved target BP control with verapamil monotherapy. The ANGINA trial showed 40% reduction in angina episodes compared to placebo. Cardiologists consistently rate Isoptin highly for its predictable pharmacokinetics and well-established safety profile. Patient satisfaction surveys indicate good tolerability with appropriate dose management.